君圣泰医药-B任命Filip Surmont博士为首席医学官 强化心肾代谢系统疾病(CKM)布局
HIGHTIDEHIGHTIDE(HK:02511) Zhi Tong Cai Jing·2026-02-02 08:43

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) has appointed Dr. Filip Surmont as Chief Medical Officer to oversee the company's medical strategy, clinical development, and related medical affairs, aiming to enhance the research and value of its core pipeline in the cardiovascular, kidney, and metabolic (CKM) disease area [1] Group 1 - The appointment of Dr. Filip Surmont is expected to strengthen the company's focus on its medical strategy [1] - Dr. Surmont will be responsible for clinical development and related medical affairs [1] - The company aims to advance its core pipeline in the CKM disease sector [1]

HIGHTIDE-君圣泰医药-B任命Filip Surmont博士为首席医学官 强化心肾代谢系统疾病(CKM)布局 - Reportify